Charcot-Marie-Tooth (CMT) neuropathies, with a frequency of approximately 1 in 2500, comprise a heterogeneous group of disorders, with typical onset in adulthood. Clinical phenotypes of these neuropathies include slowed nerve conduction velocity, muscle weakness and atrophy, and sensory and motor disturbance.[@bib1] Disease progression and severity are known to vary among individuals and even within families. Among CMT neuropathies, type 1A comprises the largest fraction, a majority of which have been linked with a 1.5-Mb duplication on the short arm of the human chromosome 17.[@bib2] The peripheral myelin protein 22 *(PMP22)* gene was mapped to this duplicated region, which results in three copies of the gene.[@bib3] Although PMP22 is expressed broadly in the body, affected individuals present with a peripheral neuropathy that varies in severity.

PMP22 was first discovered in peripheral nerves as an abundant glycoprotein named PAS-II[@bib4] and then cloned from NIH3T3 fibroblasts as growth arrest specific gene 3 (*gas-3*).[@bib5] Subsequently, PMP22 was identified as a 22-kDa transmembrane protein constituent of PNS myelin, a cell surface glycoprotein expressed mostly in myelinating Schwann cells.[@bib6] In peripheral nerves, PMP22 is enriched in the compact portion of Schwann cell myelin, where it is believed to be a structural component.[@bib7], [@bib8] Besides having roles in the process of myelination, the expression level of PMP22 has been shown to impact cell cycle progression, as well as cell spreading and migration.[@bib8], [@bib9], [@bib10] Aberrant expression of PMP22 is also known to impact cellular proteostasis as the overproduced or mutated protein is prone to aggregation.[@bib11], [@bib12] In animal models of CMT1A, affected nerves contain abnormal cytosolic aggregates of PMP22, which are reactive for ubiquitin and are surrounded by autophagic-lysosomal structures.[@bib13] Cytosolic accumulation of PMP22 in Schwann cells from a CMT1A patient has also been observed,[@bib14] indicating that elevated expression of PMP22 elicits a detectable subcellular phenotype.

A number of spontaneous and genetically engineered animal models that incorrectly express PMP22 replicate the defects seen in neuropathic patients, including slowed nerve conduction velocity, dysmyelinated and demyelinated axons, overproliferating Schwann cells, and excess deposits of endoneurial tissue.[@bib9], [@bib15], [@bib16] The animal models have allowed mechanistic investigations of the neuropathies, as well as therapy testing, yet the findings from the rodent studies have not translated to humans. The disappointing results from the multicenter ascorbic acid trial,[@bib17] which was based on preclinical studies in mice,[@bib18] recommend the need for additional models for therapy testing.

Although peripheral nerves are accessible for biopsy, and human Schwann cells survive in culture,[@bib19] performing nerve biopsies in neuropathic patients might not be ideal due to potential complications. Because dermal fibroblasts from genetic diseases offer an amenable model for investigations of cellular pathology,[@bib20] cells from genetically diagnosed CMT1A patients were examined. Here, we show that compared to nondiseased human fibroblasts, cells from neuropathic patients are slow to proliferate, express elevated levels of PMP22 mRNA, and contain ubiquitin-reactive proteasome substrates and abnormal cytosolic PMP22 aggregates. These subcellular changes lead to decreased efficiency in proteasome activity and an up-regulation of autophagy-lysosomal proteins.

Materials and Methods {#sec1}
=====================

Fibroblast Cultures {#sec1.1}
-------------------

Human skin fibroblasts from four CMT1A patients (GM05148, GM05167, GM05146, and GM05165) were purchased from the Coriell Institute (Camden, NJ). Skin fibroblasts from non-neuropathic individuals were obtained from either the Coriell Institute (GM11091), or from volunteers under an institutional review board--approved protocol at the University of Florida (Gainesville, FL; MD09, MD13, and MD16) ([Table 1](#tbl1){ref-type="table"}). All procedures with the human cells were performed in compliance with institutional review board--approved procedures. Cultures were maintained in Dulbecco\'s modified Eagle\'s medium supplemented with 15% to 20% fetal bovine serum and 20 mmol/L [l]{.smallcaps}-glutamine (Gibco, Gaithersburg, MD). Cells were expanded once per week by dissociation with 0.05% trypsin and used for experiments under 10 passages.Table 1List of Studied Cells with Donor InformationSampleAge, yearsSample IDControl 1 (C1)17GM11091Control 2 (C2)21MD13Control 3 (C3)34MD16Control 4 (C4)56MD09CMT1A Patient 1 (P1)17GM05148CMT1A Patient 2 (P2)28GM05167CMT1A Patient 3 (P3)40GM05146CMT1A Patient 4 (P4)51GM05165

Cell Proliferation Studies {#sec1.2}
--------------------------

Fibroblasts on poly-[l]{.smallcaps}-lysine--coated coverslips (10^5^ cells/cm^2^) were maintained in normal growth medium for 24 hours before incubation with bromodeoxyuridine (BrdU; Roche, Nutley, NJ). After a 4-hour incubation with BrdU, the cells were fixed with acetone/methanol (1:3) for 20 minutes, denatured in 2.5 N HCl for 30 minutes at 37°C, rinsed in phosphate-buffered saline (PBS), and processed for immunolabeling with mouse anti-BrdU (Millipore, Billerica, MA) and rabbit anti-Ki67 (EnCor, Gainesville, FL) antibodies, overnight at 4°C. Bound primary antibodies were detected with Alexa-dye--conjugated goat anti-mouse and goat anti-rabbit secondary antibodies (Invitrogen, Carlsbad, CA). Nuclei were stained with Hoechst dye (Invitrogen) and coverslips were mounted with ProLong Antifade mounting medium (Invitrogen). For quantification, BrdU- and Ki67-positive cells in 12 to 70 fixed fields (0.8 mm^2^) were counted and divided by the total number of cells (Hoechst dye--positive).

Real-Time PCR {#sec1.3}
-------------

Confluent cultures, after 48 hours incubation in 2% FCS containing growth medium, were harvested in QIAzol lysis reagent (Qiagen, Germantown, MD), and total RNA was isolated as per the manufacturer\'s instructions. Total RNA (900 ng) was reverse transcribed using the High-Capacity RNA-to-cDNA kit (Applied Biosystems, Foster City, CA). For quantitative real-time PCR analyses, undiluted cDNA and primers specific for the human PMP22 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Real Time Primers, Elkins Park, PA) were used with the LightCycler 480 SYBR Green I Master. The following forward: 5′-GTATCATCGTCCTCCACGTC-3′, and reverse: 5′-GGCAGAAGAACAGGAACAGA-3′ primers were used. Primers were designed to amplify the coding region of the human *PMP22* gene, recognizing both exon 1A-- and exon 1B--containing transcripts.[@bib21] The relative expression of PMP22 to GAPDH mRNA was determined using the 2^−ΔΔCT^ method.[@bib22]

Immunolabeling with Antibodies and Organelle Markers {#sec1.4}
----------------------------------------------------

Cells, plated on poly-[l]{.smallcaps}-lysine--coated glass coverslips at 10^5^ cells/cm^2^, were maintained in normal growth media until approximately 80% confluence. For all immunolabeling experiments other than vimentin, the cells were maintained in Dulbecco\'s modified essential medium supplemented with 2% fetal bovine serum for the last 48 hours. Subsequently, the samples were fixed with 2% paraformaldehyde in 0.1 mol/L PBS for 20 minutes, followed by rinses in PBS and permeabilization with 0.2% Triton-X 100 in PBS for 10 minutes, all at 25°C. After blocking in 5% normal goat serum diluted in PBS, the cells were incubated with primary antibodies ([Table 2](#tbl2){ref-type="table"}) overnight at 4°C. To detect PMP22, a rabbit polyclonal antibody against a 16--amino acid peptide corresponding to the second extracellular loop of the human PMP22 was used.[@bib16], [@bib23] A mouse monoclonal anti-PMP22 antibody (Chemicon, Temecula, CA) was used for double immunostaining with polyclonal LC3 or LAMP1. To label the Golgi, cells were incubated with fluorescein isothiocyanate--conjugated Vicia Villosa Lectin (Invitrogen).[@bib24] Fluorochrome-conjugated secondary antibodies (goat anti-rabbit and goat anti-mouse) were purchased from Invitrogen and were diluted in PBS with 5% normal goat serum. Nuclei were stained with Hoechst dye (Invitrogen). Coverslips were mounted using ProLong Antifade mounting medium (Invitrogen). Images were acquired on a Leica Spinning disk confocal microscope (Leica, Wetzlar, Germany), and formatted in Adobe Photoshop software version 5.5 (Adobe Systems, San Jose, CA).Table 2List of Antibodies Used in This StudySpeciesAntigenSourceCatalog no.DilutionWBIFMouseBrdUMillipore clone 131--14,871MAB4072NA1:1000RabbitKi67EnCor Biotechnology Inc.RPCA-Ki67NA1:2000MouseVimentinSigma-AldrichV5255NA1:1000RabbitHu-PMP22References [@bib16] and [@bib23]NA1:10001:1000Mouseα-TubulinSigma-AldrichT61991:5000NARabbitPDIStressgenSPA-890NA1:500RabbitUbiquitinDako CytomationZ0458NA1:1000RabbitUbiquitinEnCor Biotechnology Inc.RPCA-Ubi-11:2000NARabbitGAPDHEnCor Biotechnology Inc.RPCA-GAPDH1:30,000NARabbitLAMP1AbcamAb241701:1000NARabbitp62BiomolF480101:1000NARabbitTFEB N-TerminalSigma-AldrichSAB45031541:1000NARabbitLC3Cell Signaling Technology27751:10001:200MouseActinSigma-AldrichA38531:10,000NAMouseβ-TubulinEnCor Biotechnology Inc.MCA-1B121:10,000NAMousePMP22ChemiconMAB5306NA1:200RabbitCathepsin DFitzgerald Industries International20C-CR2013RPNA1:500[^1]

Biochemical Assays {#sec1.5}
------------------

For Western blotting, mouse sciatic nerve lysates from wild-type, C22, or PMP22-knockout mice (4 μg/lane) were blotted with anti-human PMP22-specific polyclonal antibody.[@bib25] Confluent cultures of dermal fibroblasts, after 48 hours incubation in 2% FCS containing medium, were lyzed in sample buffer \[62.5 mmol/L Tris, 3% SDS, and 10% glycerol, with complete protease (Roche) and phosphatase (Sigma-Aldrich, St. Louis, MO) inhibitors\]. Protein concentration was determined using the Bradford method (Pierce Coomassie Plus; Thermo Fisher Scientific, Waltham, MA), and samples were denatured by adding β-mercaptoethanol and boiling for 10 minutes. Equal protein amounts were resolved on SDS polyacrylamide gels and transferred to polyvinylidene difluoride membranes. Membranes were rinsed in Tris-buffered saline with 0.05% Tween-20, blocked in 5% nonfat milk, and then probed with the indicated primary antibodies ([Table 2](#tbl2){ref-type="table"}) overnight at 4°C. Bound antibodies were detected using Western Lightning Plus ECL reagents (Perkin Elmer, Waltham, MA). Films were digitally imaged using a GS-710 densitometer (Bio-Rad Laboratories, Hercules, CA) or a ChemiDoc MP Imaging System (Bio-Rad Laboratories) and analyzed using ImageJ software version 1.45 (NIH, Bethesda, MD; [*http://imagej.nih.gov/ij*](http://imagej.nih.gov/ij){#intref0010}). All biochemical experiments were repeated at least three times using protein lysates from independent cultures.

Ub-GFP Transfection {#sec1.6}
-------------------

A fixed number of cells (4 × 10^6^) were transfected with either the green fluorescent protein (GFP)-containing vector Ub-G76V-GFP[@bib26] or pmaxGFP (Lonza, Basel, Switzerland) plasmids using the Amaxa Lonza Nucleofector kit (VPD-1001), as per the manufacturer\'s instructions. Cells were plated on poly-[l]{.smallcaps}-lysine--coated glass coverslips, and the medium was replaced after 3 hours. Electroporation efficiency was determined by counting the pmaxGFP-positive cells, 24 hours post-transfection. To a subset of Ub-G76V-GFP samples, we added lactacystin (10 μmol/L; Calbiochem, San Diego, CA) as a positive control for proteasome inhibition (data not shown). Hoechst dye was used to label the nuclei, and cell images were acquired 24 hours post-transfection with a SPOT digital camera (Diagnostic Instrumentals, Sterling Heights, MI) attached to a Nikon Eclipse E800 microscope (Nikon, Tokyo, Japan). GFP-positive cells were graphed as the percentage of total (Hoechst-positive) cells.

Statistical Analysis {#sec1.7}
--------------------

For all experiments, means ± SEM were calculated and significance determined by performing unpaired two-tailed *t*-tests, using GraphPad Prism software version 5 (GraphPad Software, La Jolla, CA). *P* \< 0.05 was considered significant.

Results {#sec2}
=======

Altered Mitotic Potential of Fibroblasts from CMT1A Patients {#sec2.1}
------------------------------------------------------------

In characterizing primary skin-derived fibroblasts from CMT1A patients with verified *PMP22* gene duplication, the proliferation characteristics of the cultures were examined. Cells from four patients, representing two different families, were assigned patient (P) 1 to 4 in ascending order of donor age ([Table 1](#tbl1){ref-type="table"}). Patients 1 (GM05148) and 3 (GM05146) represent a 17-year-old son and his 40-year-old mother, whereas patient 2 (GM05167) and 4 (GM05165), represent a 28-year-old daughter and her 51-year-old father from a second donor family. According to the information provided by Coriell Institute, multiplex ligation-dependent probe amplification was used to confirm the duplication (17p) of the *PMP22* gene in all four individuals, and no mutations in the myelin protein zero (*MPZ*) gene. Clinically, the older patient from each family (Patients 2 and 4) were stated to be more affected than their children (Patients 1 and 3) at the time of biopsy. As controls, skin fibroblasts from non-neuropathic individuals with closely matched donor age range of 17 to 56 years were studied ([Table 1](#tbl1){ref-type="table"}). Because disease phenotypes in primary skin fibroblasts can disappear with extended culture time,[@bib27] all data were collected from samples under 10 passages.

To analyze the mitotic state of the studied fibroblasts, the incorporation of BrdU was measured after a 4-hour incubation in serum-rich (15% to 20% fetal bovine serum) medium. Analyses of BrdU uptake in control cultures resulted in a range from 30% to 60%, without a clear age-dependency ([Figure 1](#fig1){ref-type="fig"}A). Unexpectedly, the youngest donor-derived C1 cells had a low BrdU incorporation rate, which may be related to this individual having Alagille syndrome, per information from Coriell. Comparisons between patient (P1 to P4) and control (C2 to C4) samples detected a significant decrease in BrdU incorporation by the CMT1A cells ([Figure 1](#fig1){ref-type="fig"}A). In addition, a statistically significant age-associated reduction in BrdU incorporation was found within each of the two affected families. Over 50% fewer mitotic cells were detected in cultures from patient 3 as compared to patient 1 \[15.4% ± 2.0% versus 38.6% ± 2.5% (means ± SEM); *P* = 5.38 E-10 by *t*-test\]. Similarly, BrdU uptake decreased 3.7-fold between patients 4 and 2 \[5.9% ± 0.7 versus 21.7% ± 2.4 (means ± SEM); *P* = 3.2 E-06 by *t*-test\].Figure 1Growth characteristics and cellular morphology of dermal fibroblasts from CMT1A patients. **A** and **B:** Quantification of the percentage of cells with incorporated BrdU (**A**), or Ki67 (**B**) reactivity in cultures from control individuals (C1--C4) and CMT1A patients (P1--P4). **C:** Representative micrographs of anti-vimentin immunofluorescence of controls (C3 and C4) and CMT1A patient (P1 to P4) fibroblasts, shown in red. All cells display elongated, kite-like morphology that is characteristic of dermal fibroblasts. Data are expressed as means ± SEM. \**P* \< 0.05, \*\*\**P* \< 0.001 (*t*-test). Scale bars = 20 μm.

As an additional assay on the proliferation characteristics, the samples were labeled for Ki- 67, a nuclear protein expressed in nonquiescent cells ([Figure 1](#fig1){ref-type="fig"}B). In agreement with the BrdU-incorporation results ([Figure 1](#fig1){ref-type="fig"}A), there were significantly fewer Ki-67--positive mitotic cells in the C1 and all affected cultures (P2 to P4), relative to age-matched controls. A significant reduction in total mitotic cells was also detected within each family (*P* \< 0.001 for P1 versus P3, and for P2 versus P4). Although the proliferation rates were thus significantly reduced in patient cells, the general cell morphology across control and affected cultures appeared similar ([Figure 1](#fig1){ref-type="fig"}C). Immunolabeling with an anti-vimentin antibody did not show pronounced differences in cell shape or size between control and neuropathic samples ([Figure 1](#fig1){ref-type="fig"}C), although heterogeneity in cell size was observed. Together, these data indicate that skin fibroblasts from CMT1A patients display a reduction in mitotic potential.

PMP22 Expression and Localization in Fibroblasts from CMT1A Patients {#sec2.2}
--------------------------------------------------------------------

To determine whether the CMT1A gene duplication leads to a detectable PMP22 expression phenotype in skin fibroblasts, quantitative real-time PCR was performed. For this assay, the cells were cultured in reduced serum medium (2% fetal bovine serum) for 48 hours before analyses, to promote *PMP22* gene expression[@bib28] and to minimize differences in mitotic phenotypes. PMP22 mRNA measured by real-time PCR indicated approximately 1.5-fold higher expression in samples from the patients (P1 to P4) relative to controls (C1 to C4) ([Figure 2](#fig2){ref-type="fig"}A). Having identified low mitotic potential ([Figure 1](#fig1){ref-type="fig"}, A and B) and low PMP22 expression in the youngest control cells (C1), this sample was excluded from further analysis.Figure 2Fibroblasts from CMT1A patients express elevated levels of PMP22 mRNA and exhibit PMP22 protein aggregates. **A:** PMP22 mRNA levels in control and CMT1A patient fibroblasts, after correction for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), are graphed. Values of the control cells were normalized to 1. **B:** Sciatic nerve lysates (4 μg/lane) from human-PMP22 overexpressing (C22), wild-type (WT), and PMP22 knockout (KO) mice were immunoblotted with an anti-human PMP22 antibody. Ponceau S staining is shown as control for protein loading. Molecular mass in kDa is shown on the right. **C:** Representative micrographs of PMP22-like immunofluorescence in control (C2--C4) and CMT1A patient (P2--P4) fibroblasts after labeling with the same anti-human PMP22 antibody, as in **B**. Intracellular punctate (**arrowheads** in P2 and P3) and aggregated, perinuclear (**arrow** in P4) anti-PMP22 antibody reactive structures are marked. *n* = 3 independent cultures (**A**). \**P* \< 0.05 (*t*-test). Scale bars = 10 μm. RU, relative units.

In parallel with the PMP22 mRNA expression studies, the subcellular localization of PMP22 was examined in the dermal fibroblasts by immunofluorescence, using a polyclonal antibody against a 16--amino acid portion of the human protein.[@bib13] To document the preferential reactivity of this antibody with the human peptide, nerve lysates from human-PMP22--overexpressing C22,[@bib29] wild-type, and PMP22-null mice[@bib30] were probed ([Figure 2](#fig2){ref-type="fig"}B). As shown on the Western blot, a prominent approximately 22-kDa band was identified in nerve samples from the C22 mice, whereas a fainter band was detected in the wild-type sample. The specificity of the antibody is supported by the lack of reactivity with the PMP22-deficient nerve sample. Using this polyclonal antibody, the subcellular distribution of PMP22 was assessed in control and CMT1A patient fibroblasts ([Figure 2](#fig2){ref-type="fig"}C). In control cells (C2 to C4), PMP22 was detected on the plasma membrane and in reticular structures, likely reflecting localization in the endoplasmic reticulum (ER) and Golgi ([Figure 2](#fig2){ref-type="fig"}C). In fibroblasts from CMT1A patients (P2 to P4), prominent PMP22-like immunoreactivity was dispersed in punctate structures and in large perinuclear aggregates ([Figure 2](#fig2){ref-type="fig"}C). The large PMP22-containing perinuclear aggregates were only seen in a subset of cells (\<10% of total), and are reminiscent of the aggresomes formed by proteasome inhibition in normal Schwann cells,[@bib11] or the spontaneous PMP22 aggregates found in samples from C22 neuropathic mice.[@bib13]

To delineate the subcellular localization of PMP22 in affected fibroblasts, double labeling was performed with anti-PMP22 antibodies and ER or Golgi markers ([Figure 3](#fig3){ref-type="fig"}). Confocal microscopy was used to analyze cells from an age-matched control (C4) and the more affected CMT1A family (P2 and P4), because PMP22 aggregates were most prominent in the elder P4 ([Figure 2](#fig2){ref-type="fig"}C). As predicted from previous studies,[@bib23] PMP22-immunoreactive structures in control cells showed reticular distribution and partially co-stained with the antibody against the ER enzyme, protein disulfide-isomerase (PDI) ([Figure 3](#fig3){ref-type="fig"}A) and the Golgi marker Vicia Villosa Lectin (VVL) ([Figure 3](#fig3){ref-type="fig"}E). In CMT1A fibroblasts, reticular PMP22-like immunoreactivity was also colocalized in the ER ([Figure 3](#fig3){ref-type="fig"}, B--D) and Golgi compartments ([Figure 3](#fig3){ref-type="fig"}, F--H). The large perinuclear aggregates partially colabeled with the ER marker, PDI ([Figure 3](#fig3){ref-type="fig"}, B and [C](#fig3){ref-type="fig"}), whereas the more peripherally dispersed, small clusters of PMP22 aggregates did not ([Figure 3](#fig3){ref-type="fig"}, B and D). With regards to potential retention in the Golgi, the larger clusters of PMP22 aggregates were typically excluded from the Golgi ([Figure 3](#fig3){ref-type="fig"}G); however, an occasional PMP22-reactive aggregate displayed colabeling with VVL ([Figure 3](#fig3){ref-type="fig"}H). The distal, smaller aggregates of PMP22 did not colocalize with the Golgi marker ([Figure 3](#fig3){ref-type="fig"}, F and H). These results indicate that a fraction of the overproduced PMP22 is abnormally localized within affected cells, with a likely impact on cellular proteostasis.Figure 3The subcellular localization of the overproduced PMP22. **A--D:** Anti-PMP22 (red) and anti-protein disulfide isomerase (green) double immunofluorescence shows the distribution of PMP22 relative to the ER in control (C4) (**A**) and CMT1A patients (P2 and P4) (**B--D**) fibroblasts. **E**--**H:** PMP22 localization (red) and the Golgi marker Vicia Villosa Lectin (green) in control (C4) and CMT1A patients (P2 and P4) fibroblasts are shown. **Arrows** indicate prominent clusters of PMP22; **arrowheads**, scattered, punctate anti-PMP22 antibody immunoreactive structures; **open arrowheads**, the colocalization of PMP22 with the Golgi marker. Scale bars = 20 μm. PDI, protein disulfide isomerase; VVL, Vicia Villosa Lectin.

Compromised Cellular Proteostasis in CMT1A Fibroblasts {#sec2.3}
------------------------------------------------------

Because PMP22 is a proteasome substrate, and PMP22 aggregates are reactive for ubiquitin in CMT1A mouse models,[@bib11], [@bib12], [@bib13] double immunolabeling was performed with anti-PMP22 and anti-ubiquitin antibodies in patient-derived fibroblasts ([Figure 4](#fig4){ref-type="fig"}A). In agreement with results from the animal models, PMP22- and ubiquitin-reactive large perinuclear aggregates ([Figure 4](#fig4){ref-type="fig"}A) that were reminiscent of aggresomes formed by pharmacologic inhibition of the proteasome, were observed.[@bib11] To determine whether the fibroblasts from the patients exhibit deficits in proteasome function, multiple assays were performed ([Figure 4](#fig4){ref-type="fig"}, B--G). First, the steady-state levels of polyubiquitinated proteins whose accumulation serves as an index of ubiquitin-proteasome system congestion, was determined. There was an increase in the levels of polyubiquitinated substrates in affected samples, as compared to controls ([Figure 4](#fig4){ref-type="fig"}, B and C). Notably, patient cells from low passage numbers contained the highest levels of ubiquitinated aggregates ([Figure 4](#fig4){ref-type="fig"}B), with samples from the severely affected P4 patient being most distinguishable. Although variation in polyubiquitinated protein levels with higher cell passages were observed, the blots shown are representative of over 10 independent experiments with cells at passage 6 to 8 ([Figure 4](#fig4){ref-type="fig"}C). In agreement with the biochemical studies, immunolabeling with anti-ubiquitin antibody also revealed an abundance of ubiquitin-reactive structures in patient cells, relative to relevant age-matched control ([Figure 4](#fig4){ref-type="fig"}D). For quantification of polyubiquitinated proteins, data from independent Western blots were combined and results analyzed for control (C2 to C4) and patient (P1 to P4) cohorts. There was an approximately 1.5-fold increase in polyubiquitinated proteins in affected samples, as compared to the control group ([Figure 4](#fig4){ref-type="fig"}E).Figure 4Accumulation of undegraded proteasome substrates in fibroblasts from CMT1A patients. **A:** Anti-PMP22 and anti-ubiquitin double immunolabeling in P4 fibroblasts. **Arrows** indicate perinuclear ubiquitin-reactive PMP22 aggregate. **B** and **C**: The detection of poly-ubiquitinated substrates in cell lysates from early (**B**) and late (**C**) passage control (C2 and C3) and CMT1A (P2 and P4) cultures (20 μg/lane). Tubulin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) are shown as protein loading controls. **D:** Immunofluorescence for polyubiquitinated proteins in control (C3) and CMT1A patient fibroblasts (P2 and P4). **Inset** in P2 indicates no primary antibody control. **E:** Quantification of ubiquitin immunoblots from control and CMT1A cultures. **F:** Live-images of cells expressing an Ubi-(GFP) reporter. Nuclei are stained with Hoechst dye (blue). **G:** Quantification of Ubi-(GFP)--positive cells, represented as a percentage of total. *n* = 5 to 6 (**E**, independent lysates per sample). \**P* \< 0.05, \*\*\**P* \< 0.001 (*t*-test). Scale bars: 10 μm (**A**); 50 μm (**D** and **F**). pUbi, polyubiquitinated; Tub, tubulin.

As an additional assay for proteasome function, cells were transfected with Ubi-GFP reporter, where fluorescence indicates a buildup of nondegraded ubiquitin-tagged substrates.[@bib13], [@bib25], [@bib26] Transfection efficiency was monitored with a control GFP-plasmid and was approximately 54%. Control cells displayed minimal Ubi-GFP fluorescence indicating efficient proteasome function ([Figure 4](#fig4){ref-type="fig"}, F and G). In comparison, patient fibroblasts (P2 and P4) displayed a significantly higher percentage of Ubi-GFP--positive cells, which were most pronounced in P4 ([Figure 4](#fig4){ref-type="fig"}, F and G). Together, these results indicate that overproduction of PMP22 in primary dermal fibroblasts from CMT1A patients is associated with an impairment of proteasome activity, a cellular phenotype that is consistent between rodent Schwann cells and human fibroblasts.

Autophagy-Lysosomal Response in Neuropathic Samples {#sec2.4}
---------------------------------------------------

Because previous studies have indicated a prominent role for autophagy in PMP22 aggregate clearance and protein processing,[@bib13], [@bib31], [@bib32] it was assessed whether the autophagy-lysosomal pathway is altered in CMT1A cells ([Figure 5](#fig5){ref-type="fig"}). The levels and expression of autophagy and lysosomal proteins, including lysosome-associated membrane protein 1 (LAMP1), microtubule-associated protein light chain 3 (LC3), and p62, were determined in samples from control (C2 to C4) and neuropathic (P1 to P4) individuals ([Figure 5](#fig5){ref-type="fig"}, A--E). The levels of LAMP1 were elevated approximately 1.5-fold in patient samples, compared to the controls ([Figure 5](#fig5){ref-type="fig"}, A and B). Within the same cell lysates, the levels of LC3-II, the membrane-associated form of cytosolic LC3-I that is incorporated into the limiting membrane of autophagosomes, was evaluated.[@bib33] Levels of LC3-II were significantly higher in affected samples relative to controls ([Figure 5](#fig5){ref-type="fig"}, A and C). The ubiquitin and LC3 binding protein p62[@bib34] was also analyzed as a measure for autophagy clearance. Although p62 levels were modestly increased in patient fibroblast lysates, this difference did not reach significance ([Figure 5](#fig5){ref-type="fig"}, A and D). Similarly, the expression of transcription factor EB (TFEB), the master regulator of lysosomal and autophagy genes,[@bib35] remained comparable among the groups ([Figure 5](#fig5){ref-type="fig"}, A and E).Figure 5Autophagy-lysosomal response in fibroblasts from CMT1A patients. **A:** Western blots for LAMP1, LC3-II, p62, and TFEB on whole-cell lysates from the indicated individuals. Each membrane was reprobed with antibodies for a constitutive marker, tubulin, actin, or glyceraldehyde-3-phosphate dehydrogenase (GAPDH). **B--E:** Quantification of LAMP1, LC3-II, p62, and TFEB protein levels after immunoblotting with the respective antibodies. **F:** The detection of lysosomes in fibroblasts after labeling with LysoTracker. **G** and **H:** Confocal images of cells from CMT1A patients (P3 and P4) after double immunolabeling with anti-PMP22 (red) and anti-cathepsin D (**G**), or anti-LC3 (**H**) antibodies. In **F--H**, nuclei are stained with Hoechst dye (blue). \**P* \< 0.05, \*\**P* \< 0.01 (*t*-test). Scale bars: 50 μm (**F**); 10 μm (**G** and **H**). CatD, cathepsin D; Tub, tubulin.

To assess the subcellular distribution of autophagic-lysosomal compartments, cultures were labeled with LysoTracker Red (Invitrogen) ([Figure 5](#fig5){ref-type="fig"}F), which allows the detection of acidic compartments in living cells. Although fibroblasts from C4 and P4 displayed an abundance of perinuclear lysosomes, a subset of patient fibroblasts showed intense LysoTracker-accumulated vesicles. To characterize PMP22 distribution in relation to autophagy-lysosomal compartments, fibroblasts were co-stained with antibodies against PMP22 and the lysosomal hydrolase cathepsin D ([Figure 5](#fig5){ref-type="fig"}G) or autophagosome marker LC3 ([Figure 5](#fig5){ref-type="fig"}H). There was a partial colocalization of PMP22 with both LC3 and cathepsin D ([Figure 5](#fig5){ref-type="fig"}, G and H). Similar recruitment of autophagosomes and lysosomes near PMP22 aggregates have been observed in Schwann cells that expresses mislocalized, excess PMP22.[@bib13], [@bib36] Together, these results indicate that dermal fibroblasts from CMT1A patients share characteristics with murine neuropathic Schwann cells, including the activation and recruitment of autophagy lysosomes to PMP22 aggregates.[@bib13], [@bib36]

Discussion {#sec3}
==========

The results in this study demonstrate that dermal fibroblasts from CMT1A patients display disease phenotypes that are consistent with findings in mouse models of PMP22 neuropathies, including a cellular response to the misexpressed PMP22.[@bib12], [@bib13] In addition, similar to the detection of intracellular PMP22 aggregates seen in these patients\' fibroblasts, previous studies in nerve biopsies from CMT1A patients identified abnormally localized, cytosolic PMP22 within Schwann cells.[@bib14] The fibroblasts also reproduced one of the earliest described effects of PMP22 overexpression, namely, the inverse relationship of high protein levels with reduced cell proliferation.[@bib37] Nonetheless, dermal fibroblasts lose pathogenic phenotype with passage, which agrees with a report on cells from CMT2L patients.[@bib27] In this study, the skin fibroblasts retained a pathological phenotype up to 3 months in culture, after which they became indistinguishable from controls. Similar results were observed in the CMT1A fibroblasts, as the ubiquitinated protein accumulation, the prevalence of PMP22 aggregates, as well as the aberrant cell division phenotypes became less noticeable after extended (2 to 3 months) culture time.

The understanding of the pathobiology of human disorders, and development of therapies, has been aided by advancements in transgenic animal technologies, yet therapies that appear to work in rodents have not been effective in clinical trials. Studies of disease mechanisms and therapy testing in disease-relevant cell types derived from skin biopsies of affected individuals are of particular interest and now are possible with the induced pluripotent stem cell technology. Because skin fibroblasts can be reprogrammed into Schwann cells, one would expect that they would reproduce a disease-relevant phenotype. Indeed, a recent study by Kitani-Morii et al[@bib38] demonstrated that reprogrammed neural crest cells from CMT patients retain disease-specific molecular features. Nonetheless, successful reprogramming of CMT1A dermal fibroblasts to functional Schwann cells has not been reported, even though Schwann cells have been derived from human epidermal neural crest and other stem cells.[@bib39] Schwann cells cultured from CMT1A patient nerve biopsies displayed altered growth behavior, with decreased proliferation in all passages.[@bib40] These cells also overexpressed PMP22 mRNA, suggesting that glial cells from patients with confirmed *PMP22* gene duplication present a disease-relevant phenotype. In comparison to our findings in cultured fibroblasts and the above-cited study in human Schwann cells,[@bib40] another article reported a lack of correlation between PMP22 transcript levels in skin and nerve biopsies and disease phenotype in a cohort of CMT1A patients.[@bib41] This later study examined samples from patients in the ascorbic acid trial, and in contrast to the original publication,[@bib18] they did not report an effect of ascorbate on PMP22 expression. One difference between the mentioned studies and our work is the culturing of the cells in low-serum medium for 48 hours before analysis. This methodology was used because PMP22 transcript levels are known to increase at growth arrest.[@bib37] In general, however, PMP22 message levels appear to vary in human biopsy material, which led to the suggestion that the extra copy of the *PMP22* gene disrupts gene regulatory mechanisms.[@bib42] Furthermore, there are numerous reports on aberrant PMP22 expression in cancer biopsies, including osteosarcoma and breast cancer,[@bib43] with the levels of PMP22 expression not necessarily correlating with the mitotic state of the cells. Therefore, more studies with larger sample numbers are necessary before the precise utility of CMT1A patient--derived cells for therapy development and testing can be unequivocally established.

A somewhat unexpected and striking finding in our study is the display of disease-state--relevant phenotypes in the cultured cells. The four studied CMT1A cells represent two distinct, genetically identified CMT1A families with a parent and child. Within each of the families, cells from the older, more affected individual displayed a more pronounced disease-relevant pathological phenotype, including reduced mitotic potential and cytosolic PMP22 aggregation ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). Furthermore, cells from the most severely affected 51-year-old CMT1A patient (P4) showed the most pronounced effect on proteostasis, with highly significant impairment of proteasome activity ([Figure 4](#fig4){ref-type="fig"}). In fact, in a previous study, an over 50% reduction in the chymotrypsin-like activity of the proteasome, and an over threefold increase in undegraded substrates in P4 cells was reported.[@bib25] Elevating chaperone expression through pharmacologic induction of the heat shock response, alleviated the proteasome dysfunction, supporting the utility of these cells for *in vitro* drug screening.[@bib25] In agreement with our current data, aging indeed is a key risk factor in hereditary neurodegenerative disorders, because the efficacies of protein quality control mechanisms, including the proteasome, are known to decline across the lifespan.[@bib44]

In CMT1A, increasing evidence indicates that the disease mechanism involves failure to process and deliver sufficient PMP22 to myelin, which is underlined by defects in the ubiquitin-proteasome system and cellular proteostasis.[@bib45] When proteasome function is overburdened by excess misfolded proteins or a pharmacologic block, PMP22 abnormally accumulates in the cytosol in aggregated structures. This reflects the importance of ubiquitin-proteasome system function for PMP22 processing, because a large proportion of newly synthesized PMP22 normally undergoes immediate degradation.[@bib23] Similarly, enhancing the ubiquitin-proteasome system through dietary restriction or pharmacologic activators improved PMP22 processing in mouse CMT1A Schwann cells and increased their myelination capacity.[@bib31], [@bib46] The pathological phenotype of proteasome impairment discovered in mouse models of CMT1A is preserved in fibroblast from neuropathic patients, which signifies the fundamental nature of how cells respond to the overproduced PMP22. Indeed, cellular stress in response to PMP22 overexpression has been observed in many different cell types and can lead to cell death under certain conditions.[@bib47]

The data described suggest that dermal skin fibroblasts provide a suitable model for therapeutic studies of CMT1A. Our findings are consistent with a recent report in fibroblasts from giant axonal neuropathy patients where abnormal intermediate filament organization was retained in the culture model.[@bib20] This article led to the detection of altered mitochondrial mobility in affected samples and allowed for correction of the defect by silencing the disease gene. Similarly, dermal fibroblasts from CMT1A patients provide an accessible model where suppression of the overproduced PMP22 can be attained and functional correction of the aberrant mitotic phenotype can be assessed. Using such a simple assay, if consistent across a larger sample set, would provide an ideal platform for drug testing and may lead to new candidate molecules.
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[^1]: GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IF, immunofluorescence; NA, not applicable; PDI, protein disulfide-isomerase; WB, Western blot.
